BioDelivery Sciences International, Inc. (BDSI)

Check out top investors' recommendation for BDSI
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
4.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer; BEMA Buprenorphine that is in Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population; BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence; and BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. The company has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Scott Henry Roth Capital Partners LLC Buy   Nov 13, '17     5.00  Nov 13, '18  N/A 
David Amsellem Piper Jaffray Buy   Oct 20, '17     4.00  Oct 20, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Oct 12, '17     5.00  Oct 12, '18  N/A 
David Amsellem Piper Jaffray Buy   Sep 15, '17     4.00  Sep 15, '18  N/A 
Ken Trbovich C.K. Cooper & Company Buy   Jul 24, '17     4.00  Jul 24, '18  N/A 
Corey Davis Jefferies & Co. Buy   Jul 24, '17     4.00  Jul 24, '18  N/A 
David Amsellem Piper Jaffray Buy   Jul 10, '17     3.00  Jul 10, '18  N/A 
Corey Davis Jefferies & Co. Buy   May 26, '17     4.00  May 26, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   May 16, '17     4.50  May 16, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Oct 28, '16     7.00  Oct 28, '17  N/A 
David Amsellem Piper Jaffray Buy   May 12, '16   2.06  4.00  May 12, '17  -7.77% 
David Amsellem Piper Jaffray Buy   Feb 08, '16   3.72  6.00  Feb 08, '17  -47.58% 
Scott Henry Roth Capital Partners LLC Buy   Nov 10, '15   5.91  14.00  Nov 10, '16  -67.85% 
Scott Henry Roth Capital Partners LLC Buy   Oct 06, '15   6.23  14.00  Oct 06, '16  -60.19% 
Tim Lugo William Blair & Company, L.L.C. Buy   Sep 08, '15   6.66  17.00  Sep 08, '16  -62.16% 
Scott Henry Roth Capital Partners LLC Buy   May 11, '15   7.64    May 11, '16  -71.47% 
Charles Duncan Piper Jaffray Buy   Apr 22, '15   9.26    Apr 22, '16  -60.15% 
Scott Henry Roth Capital Partners LLC Buy   Mar 31, '15   10.50  16.00  Mar 31, '16  -68.10% 
Charles Duncan Piper Jaffray Buy   Dec 30, '14   12.42    Dec 30, '15  -60.31% 
James Molloy Janney Capital Markets Buy   Dec 30, '14   12.42    Dec 30, '15  -60.31% 
< previous12